
Commentary|Videos|November 16, 2023
CABINET: Cabozantinib Versus Placebo in Patients With Advanced Neuroendocrine Tumors After Progression on Everolimus
Expert medical oncologists review data from the CABINET trial evaluating cabozantinib compared with placebo in two cohorts of previously treated patients with neuroendocrine tumors.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
June 2026 in Oncology: A Look Back at FDA Approvals and Decisions
2
New Considerations Arise in Sequencing After Second Relapse in Multiple Myeloma
3
Orca-T Gains FDA Approval in Matched Donor Transplants
4
SC Amivantamab Plus Lazertinib Builds on Evolving Frontline Paradigm in EGFR+ NSCLC
5









































